ES2109929T3 - Procedimiento para preparar un glucano de levadura - Google Patents

Procedimiento para preparar un glucano de levadura

Info

Publication number
ES2109929T3
ES2109929T3 ES91111143T ES91111143T ES2109929T3 ES 2109929 T3 ES2109929 T3 ES 2109929T3 ES 91111143 T ES91111143 T ES 91111143T ES 91111143 T ES91111143 T ES 91111143T ES 2109929 T3 ES2109929 T3 ES 2109929T3
Authority
ES
Spain
Prior art keywords
glucan
crustacea
stimulate
beta
subphylum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91111143T
Other languages
English (en)
Inventor
Gunnar Rorstad
Borre Robertson
Jan Raa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcticzymes Technologies ASA
Original Assignee
Biotec Mackzymal ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotec Mackzymal ASA filed Critical Biotec Mackzymal ASA
Application granted granted Critical
Publication of ES2109929T3 publication Critical patent/ES2109929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCESO PARA ESTIMULAR EL SISTEMA INMUNOLOGICO DE LOS ANIMALES ACUATICOS DE LA CLASE OSTEICHTIES Y CRUSTACEA SUBPHYLUM QUE COMPRENDEN LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UNA GLUCANO DE PARED DE CELULA DE LEVADURA COMPUESTO DE UNIDADES DE GLUCOPIRANOSA ENLAZADAS PREDOMINANTEMENTE POR ENLACES BETA-1,3 GLUCOSIDICO, QUE TIENE AL MENOS UNA RAMA DE ESTE COMPUESTO DE UNIDADES DE GLUCOPIRANOSA ENLAZADAS POR ENLACES BETA-1,6 GLICOSIDICOS. ADEMAS LA INVENCION SE REFIERE A UN PROCESO PARA MEJORAR EL EFECTO DE LAS VACUNAS ADMINISTRANDO UNA CANTIDAD EFECTIVA DEL GLUCANO DE PARED DE CELULA DE LEVADURA JUNTO CON LOS ANTIGENO DE VACUNA. ESTA INVENCION TAMBIEN SE REFIERE A UN PROCESO PARA OBTENER UN GLUCANO PARTICULARMENTE EFECTIVO PARA ESTIMULAR EL SISTEMA INMUNOLOGICO DE LOS ANIMALES ACUATICOS DE LA CLASE OSTEICHTHYES Y CRUSTACEA SUBPHYLUM.
ES91111143T 1990-07-06 1991-07-04 Procedimiento para preparar un glucano de levadura Expired - Lifetime ES2109929T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54957590A 1990-07-06 1990-07-06

Publications (1)

Publication Number Publication Date
ES2109929T3 true ES2109929T3 (es) 1998-02-01

Family

ID=24193557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91111143T Expired - Lifetime ES2109929T3 (es) 1990-07-06 1991-07-04 Procedimiento para preparar un glucano de levadura

Country Status (12)

Country Link
US (1) US5401727A (es)
EP (1) EP0466037B1 (es)
JP (1) JP2828799B2 (es)
AT (1) ATE160787T1 (es)
AU (1) AU628752B2 (es)
CA (1) CA2040374C (es)
DE (1) DE69128308T2 (es)
DK (1) DK0466037T3 (es)
ES (1) ES2109929T3 (es)
FI (1) FI104537B (es)
GR (1) GR3026130T3 (es)
NO (1) NO305705B1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665649B2 (ja) * 1991-02-01 1994-08-24 台糖株式会社 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
DK0664671T3 (da) * 1993-08-06 2003-01-06 Biotec Pharmacon Asa Dyrefoder omfattende gærglucan
JPH08113539A (ja) * 1993-09-22 1996-05-07 Nippon Paper Ind Co Ltd 免疫増強剤及びその製造方法、並びにそれを用いた甲殻類及び魚類の養殖用飼料
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5871751A (en) * 1994-10-12 1999-02-16 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Renibacterium salmoninarum vaccine and method for its preparation
JP3744020B2 (ja) * 1995-04-14 2006-02-08 日本製紙株式会社 免疫増強剤並びにそれを含有する甲殻類、魚類及び家畜用飼料
SI0848592T1 (en) * 1995-09-05 2001-02-28 Baensch Tetra Werke Antistress agents for aquatic animals
US5722346A (en) * 1996-04-17 1998-03-03 The Board Of Governors For Higher Education Smolting feed
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
WO1998047392A1 (en) * 1997-04-18 1998-10-29 Immudyne, Inc. Gel delivery system for animal nutrition and health
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US20040127458A1 (en) * 2000-11-06 2004-07-01 Hunter Kenneth W. Beta-glucan containing compositions, methods for manufacturing beta-glucans, and for manufacturing and using beta-glucans and conjugates thereof as vaccine adjuvants
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7323140B2 (en) * 2001-03-28 2008-01-29 Handylab, Inc. Moving microdroplets in a microfluidic device
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
KR20050043751A (ko) * 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
DE10222358A1 (de) * 2002-05-21 2003-12-11 Nutrinova Gmbh ß-Glucanhaltiges Sorbinsäurepräparat als Futtermittelzusatz in der Nutztieraufzucht
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
GB0225502D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Therapeutic and prophylactic preparations
GB0225503D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Gel feed
JP2004210895A (ja) * 2002-12-27 2004-07-29 Immudyne Japan:Kk 免疫機能を有する可能性β−グルカンの製造方法及び用途
JP2007524354A (ja) * 2003-01-29 2007-08-30 イミュダイン インコーポレーティッド 動物用の免疫増強剤
GB2399752A (en) * 2003-03-26 2004-09-29 Micap Plc Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant
ES2899590T3 (es) 2004-01-23 2022-03-14 Eden Research Plc Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico
NZ551644A (en) 2004-05-20 2010-06-25 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
AU2005284727A1 (en) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
US7306818B2 (en) * 2005-01-03 2007-12-11 Promd Biotech Co., Ltd. Method for preventing and/or treating viral infection in aquatic animals
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
AU2006306228A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
BRPI0619219B8 (pt) 2005-11-30 2021-11-16 Univ Cornell Método para matar ácaros, método para tratar ou impedir a infestação por um ácaro em uma planta e uso de uma composição
WO2007063268A1 (en) 2005-11-30 2007-06-07 Eden Research Plc Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
WO2008102151A1 (en) * 2007-02-21 2008-08-28 Biotec Pharmacon Asa Medical uses of glucans
JP5153188B2 (ja) * 2007-03-30 2013-02-27 小林製薬株式会社 Ｔｈ１／Ｔｈ２バランス改善剤
US20090061049A1 (en) * 2007-08-28 2009-03-05 Vadood Azarm Feed compositions for aquatic animals and methods of making the same
US8389485B2 (en) * 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
CN101878033A (zh) * 2007-11-13 2010-11-03 生物科技医药公司 治疗或预防肠道炎症性疾病的方法
WO2009067020A1 (en) 2007-11-19 2009-05-28 Calanus As Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20100267661A1 (en) * 2009-03-17 2010-10-21 Immudyne, Inc. Beta glucans and methods of use thereof
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
CA2794189C (en) 2010-03-24 2022-01-11 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP2603450B1 (en) 2010-08-14 2016-11-02 University of Massachusetts Yeast cell wall particle for receptor-targeted nanoparticle delivery
EP2694030A2 (en) 2011-03-04 2014-02-12 Sana Pharma AS Cosmetic formulations
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
AP2016009288A0 (en) 2013-11-21 2016-06-30 Eden Research Plc Pesticidal composition
WO2015085113A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
CA2947619A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
GB201501793D0 (en) 2015-02-03 2015-03-18 Eden Research Plc Encapsulation of high potency active agents
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
EP3138573A1 (en) * 2015-07-09 2017-03-08 Danstar Ferment AG Compositions and methods for stimulating immune responses in human and/or animal
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
CN106719136A (zh) * 2016-11-30 2017-05-31 蚌埠市渔歌农业科技有限公司 一种防治鲶鱼病害的养殖方法
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
JP6530846B1 (ja) * 2018-10-09 2019-06-12 アサヒグループホールディングス株式会社 免疫賦活剤及び感染予防方法
CA3160657A1 (en) 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
US20240226135A1 (en) * 2021-05-21 2024-07-11 Asahi Group Holdings, Ltd. Immunostimulator and method of producing glucan composition
IL322261A (en) 2023-02-09 2025-09-01 Alnylam Pharmaceuticals Inc Reverser molecules and methods of using them
WO2025078537A1 (en) 2023-10-10 2025-04-17 Ab Mauri (Uk) Ltd Compositions comprising branched (1,3)(1,6)-beta-glucans for use in the treatment of cancer
WO2025078523A1 (en) 2023-10-10 2025-04-17 Ab Mauri (Uk) Ltd Compositions comprising a combination of (1,3)(1,6)-beta-glucans and uses thereof in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301848A (en) * 1962-10-30 1967-01-31 Pillsbury Co Polysaccharides and methods for production thereof
GB2076418A (en) * 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
JPS6120561A (ja) * 1984-07-09 1986-01-29 住友ベークライト株式会社 医療用吸着剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
JPS6337801A (ja) * 1986-07-31 1988-02-18 Matsushita Electric Ind Co Ltd タ−ンテ−ブル
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine

Also Published As

Publication number Publication date
DE69128308T2 (de) 1998-03-26
FI104537B (fi) 2000-02-29
AU628752B2 (en) 1992-09-17
ATE160787T1 (de) 1997-12-15
JP2828799B2 (ja) 1998-11-25
CA2040374A1 (en) 1992-01-07
FI913275A0 (fi) 1991-07-05
NO912645D0 (no) 1991-07-05
AU7933891A (en) 1992-01-23
NO305705B1 (no) 1999-07-12
CA2040374C (en) 1998-06-16
NO912645L (no) 1992-01-07
EP0466037A2 (en) 1992-01-15
EP0466037A3 (en) 1992-10-28
GR3026130T3 (en) 1998-05-29
JPH04253703A (ja) 1992-09-09
US5401727A (en) 1995-03-28
DE69128308D1 (de) 1998-01-15
EP0466037B1 (en) 1997-12-03
FI913275L (fi) 1992-01-07
DK0466037T3 (da) 1998-08-10

Similar Documents

Publication Publication Date Title
DK0466037T3 (da) Fremgangsmåde til fremstilling af et gærglucan
ES2155540T3 (es) Adyuvante para vacunas que comprende un polisacarido sulfolipidico hidrofobo.
ES2118109T3 (es) Antigenos polisacaridos de streptococcus pneumoniae.
ES2112270T3 (es) Anticuerpo de recombinacion especifica del cd4.
ES2191016T3 (es) Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
ES2099744T3 (es) Sistema de localizacion.
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
ES2084827T3 (es) Composiciones de vacuna mejoradas.
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ATE166530T1 (de) Vorrichtung zur frühembryonalen in ovo injektion
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
ATE255419T1 (de) Für den vogelembryo geeignete multivalente impfstoffe
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
GB1183506A (en) New vaccines for combating influenza and the preparation thereof
MX9301014A (es) Composiciones citoprotectora y metodos para preparar y usar las mismas.
NL165217C (nl) Werkwijze voor het bereiden van een vaccin voor het immuniseren van pluimvee tegen de ziekte van marek.
AR023536A1 (es) Vacunas
ATE211923T1 (de) Parenterale immunisierung gegen rotavirus
ES8707296A1 (es) Un metodo para producir anticuerpos monoclonales humanos
ES544306A0 (es) Procedimiento de producir antigenos relacionados con el enlace glicosidico derivados de cancer.
ES2055610T3 (es) Vacuna contra hrsv.
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 466037

Country of ref document: ES